TiGenix Reaches Major Cell Therapy Milestone With 1000th Implant Of Chondrocelect
Published: Feb 04, 2014
LEUVEN, Belgium, Feb. 4, 2014 (GLOBE NEWSWIRE) -- TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it reached a major milestone with the performance of the 1000th ChondroCelect implantation for cartilage repair in the knee. ChondroCelect is the first cell therapy that was granted approval by the European Medicines Agency (EMA) as an Advanced Therapy Medicinal Product (ATMP). Today it is routinely used in orthopedic centers of excellence across several European countries.
Help employers find you! Check out all the jobs and post your resume.